Corneal Changes After Belantamab Mafodotin in Multiple Myeloma Patients
Rebecca B Bausell1, Arshia Soleimani, Alfred Vinnett
1Department of Ophthalmology and Visual Sciences (R.B.B., A.V., M.D.B., B.H.J., W.M.M.), University of Maryland School of Medicine, Baltimore, MD; The Marlene and Stewart Greenebaum Cancer Center (A.S., S.A.S., K.B., A.Z.B.), University of Maryland School of Medicine, Baltimore, MD.
Eye & Contact Lens
|December 11, 2020
Summary
Belantamab mafodotin (belamaf) treatment for multiple myeloma caused progressive corneal microcyst-like epithelial changes (MECs). These changes resolved upon treatment cessation but recurred upon reinitiation, indicating a link between belamaf and ocular toxicity.
Area of Science:
- Ophthalmology
- Oncology
- Pharmacology
Background:
- Refractory multiple myeloma (MM) treatment often involves novel therapeutics.
- Belantamab mafodotin (belamaf) is an investigational antibody-drug conjugate targeting B-cell maturation antigen (BCMA).
Purpose of the Study:
- To document and characterize corneal microcyst-like epithelial changes (MECs) observed in patients receiving belantamab mafodotin.
- To investigate the potential association between belamaf therapy and limbal stem cell dysfunction (LSCD).
Main Methods:
- A single-center case series was conducted.
- 12 patients with refractory multiple myeloma undergoing belamaf treatment were analyzed.
Main Results:
- All 12 patients developed MECs, initially peripheral and progressing centrally.
- MECs regressed upon belamaf cessation and recurred upon retreatment.
- Eight patients exhibited corneal staining indicative of LSCD with prolonged therapy.
Conclusions:
- Belantamab mafodotin administration is associated with the development of MECs and LSCD.
- Further research is required to elucidate the etiology of MECs and the mechanism of LSCD in this context.
Related Concept Videos
01:28Angle Closure Glaucoma: Treatment
960
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
960
01:27Open Angle Glaucoma: Treatment
836
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
836